Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
PTC Therapeutics’ Translarna for nmDMD is Conditionally Approved in European Union
Recent Posts
- This ALS caregiver is learning to hit the pause button
- Oral prosetin proves safe in early trial, paving way for Phase 2
- Adult children of parents with ALS may need more support, study finds
- A funny thing happened on the way to the ALS forums
- Motor neuron diseases are on the increase in Europe, study finds